Inherited deficiency of lysosomal acid maltase (GAA) results in glycogen storage disease type II (GSD-II) or acid maltase deficiency. Infantile-onset patients (Pompe's disease) present with massive accumulation of glycogen in cardiac and skeletal muscle, resulting in death in the first year of life. In contrast, adult-onset patients have manifestations limited to skeletal muscle. Currently, there is no treatment or cure for the disease. Gene therapy for diseases that affect cardiac and skeletal muscles or organs (such as GSD-II) may be very difficult because of size, location and transfection efficiency. In ongoing studies in normal mice and in an affected bovine model, we have utilized a vector carrying the cytomegalovirus (CMV) promoter and the human GAA cDNA combined with liposome-complexed DNA in attempts to correct the defect. We demonstrated that the plasmid is taken up by tissues, including skeletal and heart muscle, for three months after a single infusion. However, no control or regulation for over-expression is possible with this system. We therefore propose to develop a muscle-specific regulatory vector system that will control for over-expression and tissue specificity. We will construct a series of vectors containing the cytomegalovirus or creatine kinase or heavy chain myosin promoters-enhancers, plus a prokaryotic regulatory element that turns off transcription in the presence of doxycycline (Dox). We will subclone the human GAA cDNA into each vector. We will also transfect the minigene(s) into human GSD-II fibroblast and muscle cells, plus murine and human tissue culture cells, including muscle, skin and lymphoid cells. Cells will be cultured with and without various levels of Dox. Human GAA transcription, translation and expression will be assessed by GAA enzyme activity, GAA protein by rocketimmunoelectrophoresis (RIE) and Western analysis and human GAA mRNA by Northern analysis. The laboratory was used for oligonucleotide synthesis, DNA sequencing, Southern analysis, ELISA, and recombinant DNA techniques.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
39
Fiscal Year
2000
Total Cost
$21,006
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Homann, O R; Misura, K; Lamas, E et al. (2016) Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. Mol Psychiatry 21:1690-1695
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Li, Yi; Tsui, Wai; Rusinek, Henry et al. (2015) Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med 56:270-3
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23
Beecham, Gary W; Dickson, Dennis W; Scott, William K et al. (2015) PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 84:972-80

Showing the most recent 10 out of 470 publications